{"id":"NCT01059812","sponsor":"Novo Nordisk A/S","briefTitle":"A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes","officialTitle":"A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes (BOOSTâ„¢: INTENSIFY ALL)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-02-01","primaryCompletion":"2010-12-23","completion":"2010-12-23","firstPosted":"2010-02-01","resultsPosted":"2015-11-20","lastUpdate":"2018-12-20"},"enrollment":424,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"insulin degludec/insulin aspart","otherNames":[]},{"type":"DRUG","name":"biphasic insulin aspart 30","otherNames":[]}],"arms":[{"label":"IDegAsp BID","type":"EXPERIMENTAL"},{"label":"BIAsp 30 BID","type":"ACTIVE_COMPARATOR"}],"summary":"This trial is conducted in Asia. The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart (IDegAsp)) with biphasic insulin aspart (BIAsp) 30 in patients with type 2 diabetes not optimally controlled on once or twice daily insulin with or without metformin.","primaryOutcome":{"measure":"Change in HbA1c (Glycosylated Haemoglobin) After 26 Weeks of Treatment","timeFrame":"Week 0, Week 26","effectByArm":[{"arm":"IDegAsp BID","deltaMin":-1.38,"sd":0.88},{"arm":"BIAsp 30 BID","deltaMin":-1.42,"sd":0.97}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":46,"countries":["Hong Kong","Japan","Malaysia","South Korea","Taiwan"]},"refs":{"pmids":["27553066","26612062","27059529","29451706","30474818","35044568","25498130"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":279},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Diabetic retinopathy"]}}